Outcomes after resumption of immune checkpoint inhibitor therapy after high-grade immune-mediated hepatitis.

ABSTRACT:

Background

In the current study, the authors assessed the risks and outcomes of immune checkpoint inhibitor (ICI) rechallenge in patients with resolved grade 3 to 4 ICI hepatitis because current guidelines recommend permanent ICI discontinuation in these patients.

Methods

The authors performed a retrospective cohort study from 2010 through 2019 of patients with melanoma who were treated with ≥1 ICIs and who recovered from grade 3 to 4 ICI hepatitis. The primary outcome was hepatitis recurrence and the secondary outcome was the development of any immune-related adverse event (irAE) requiring the discontinuation of ICI rechallenge. Best overall response and time to all-cause death were compared between the patients who did and those who did not undergo ICI rechallenge. Grading

SUBMITTER: Li M 

PROVIDER: S-EPMC7655516 | biostudies-literature | 2020 Dec

REPOSITORIES: biostudies-literature